Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study.

CONCLUSION: This study confirms that metformin is transported into tumor tissue in women with breast cancer. This finding support that metformin may have direct anti-neoplastic effects on tumor cells in breast cancer patients. However, distribution of metformin in tumor tissue is markedly lower than in liver, an established metformin target tissue. PMID: 32240455 [PubMed - as supplied by publisher]
Source: Biomed Res - Category: Research Authors: Tags: Breast Cancer Res Treat Source Type: research

Related Links:

ConclusionThis study confirms that metformin is transported into tumor tissue in women with breast cancer. This finding support that metformin may have direct anti-neoplastic effects on tumor cells in breast cancer patients. However, distribution of metformin in tumor tissue is markedly lower than in liver, an established metformin target tissue.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionCertain histologic subtypes of breast cancer are associated with preferential DMS and prognosis; this knowledge may help to further understand the mechanism of breast cancer metastasis and to monitor the prognosis of patients with TNBC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient w...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion MTDH is pro-oncogenic factor playing multifaceted and diverse roles in cancer progression. Its association and central role in regulating signaling pathways such a MAPK, wnt/β-catenin, PI3K/AkT, NF-κβ pathways in various cancers shows that it plays a vital role in metastasis. MTDH contribution to chemo and radiotherapy resistance provides a new direction for the development of anticancer therapeutics. Multiple mechanisms converge to promote expression of MTDH in cancers. Further studies are therefore warranted to determine whether the elevated MTDH expression has prognostic value for development...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The texture analysis for breast DCE-MRI proposed in this study demonstrated potential utility in HER2 2+ status discrimination. Background Human epidermal growth factor receptor 2 (HER2) is an orphan tyrosine kinase receptor. It is reported that HER2 is overexpressed in 15–20% of breast cancers. Overexpression of HER2 in breast cancer correlates with shortened disease-free survival. Compared with HER2-negative patients, patients with HER2-positive breast cancers have a poor prognosis, a high probability of lymph node metastasis and a high risk of recurrence (1–3). However, previous studies h...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. In vitro assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation ind...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Seon Ah Lim1†, Jungwon Kim1†, Seunghyun Jeon1†, Min Hwa Shin1, Joonha Kwon1, Tae-Jin Kim1, Kyungtaek Im1, Youngmin Han2, Wooil Kwon2, Sun-Whe Kim2, Cassian Yee3, Seong-Jin Kim4*, Jin-Young Jang2* and Kyung-Mi Lee1,3,5* 1Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, South Korea 2Department of Surgery and Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea 3Department of Melanoma Medical Oncology and Immunology, MD Anderson Cancer Center, Houston, TX, United States 4Prec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsThese preliminary data suggest that genomic profiling may predict which patients with metastatic breast cancer benefit most from radioembolization. PI3K pathway mutations are associated with improved imaging response, which is associated with longer survival.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Invasive lobular carcinoma (ILC) represents 10% of all invasive breast cancers and is the 2nd most common breast cancer after invasive ductal carcinoma. As well as spread to lymph nodes, lung and liver, ILC frequently metastasizes to the gastrointestinal tract, peritoneum, retroperitoneum and gynaecological organs.
Source: International Journal of Surgery - Category: Surgery Authors: Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Ductal Carcinoma | Epidemiology | Fortamet | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Metformin | Research | Study | Urology & Nephrology | Women